Medical Health & Life Science Research News

New report examines the retinal vein occlusion drugs pipeline therapeutics review

New report examines the retinal vein occlusion drugs pipeline therapeutics review

Retinal Vein Occlusion Pipeline Review H1 2017 report provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.The report reviews key players involved Retinal Vein Occlusion therapeutics and enlists all their major and minor projects

- Agency -.

Retinal Vein Occlusion Pipeline Review H1 2017 Pharmaceutical and Healthcare disease pipeline guide provides an overview of the Retinal Vein Occlusion (Ophthalmology) pipeline landscape. Retinal Vein Occlusion (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 1, 8 and 2 respectively.

Report at: www.reportsnreports.com/contacts/.aspx?name=1057919

Report Provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

- Agency -.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Retinal Vein Occlusion - Companies Involved in Therapeutics Development Discussed: Addmedica SAS, Aerpio Therapeutics Inc, Chengdu Kanghong Pharmaceuticals Group Co Ltd, Clearside BioMedical Inc, Formycon AG, Kala Pharmaceuticals Inc, Lupin Ltd, Mabion SA, Ocular Therapeutix Inc, Ohr Pharmaceutical Inc, ThromboGenics NV.

Retinal Vein Occlusion Drug Profiles Discussed: aflibercept biosimilar, AKB-9778, bevacizumab SR, conbercept, HO-10, hydroxyurea, KPI-285, LKA-651, ocriplasmin, OTX-TKI, Protein to Inhibit VEGF for Ophthalmology, ranibizumab biosimilar, squalamine lactate, triamcinolone acetonide.

Retinal Vein Occlusion (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Report at: www.reportsnreports.com/contacts/.aspx?name=1057919

Featured News & Press Releases Covered In Report:

Feb 16, 2017: Clearside Biomedical Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata Used Together With Eylea in Subjects with Retinal Vein Occlusion

Oct 10, 2016: Clearside Biomedical to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting

Jul 26, 2016: Clearside Biomedical Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion

Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients with Macular Edema Associated with Retinal Vein Occlusion

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion (Ophthalmology) and reviews pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources. This report also covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages as well as features descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

In this pipeline report Key companies involved in Retinal Vein Occlusion (Ophthalmology) therapeutics and enlist their entire major and minor projects are covered. Retinal Vein Occlusion (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type are deeply described in this report.

List of Tables

  1. Number of Products under Development for Retinal Vein Occlusion, H1 2017
  2. Number of Products under Development by Companies, H1 2017
  3. Products under Development by Companies, H1 2017
  4. Number of Products by Stage and Target, H1 2017
  5. Number of Products by Stage and Mechanism of Action, H1 2017
  6. Number of Products by Stage and Route of Administration, H1 2017
  7. Number of Products by Stage and Molecule Type, H1 2017
  8. Retinal Vein Occlusion - Pipeline by Addmedica SAS, H1 2017
  9. Retinal Vein Occlusion - Pipeline by Aerpio Therapeutics Inc, H1 2017
  10. Retinal Vein Occlusion - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H1 2017
  11. Retinal Vein Occlusion - Pipeline by Clearside BioMedical Inc, H1 2017
  12. Retinal Vein Occlusion - Pipeline by Formycon AG, H1 2017
  13. Retinal Vein Occlusion - Pipeline by Kala Pharmaceuticals Inc, H1 2017
  14. Retinal Vein Occlusion - Pipeline by Lupin Ltd, H1 2017
  15. Retinal Vein Occlusion - Pipeline by Mabion SA, H1 2017
  16. Retinal Vein Occlusion - Pipeline by Ocular Therapeutix Inc, H1 2017
  17. Retinal Vein Occlusion - Pipeline by Ohr Pharmaceutical Inc, H1 2017
  18. Retinal Vein Occlusion - Pipeline by ThromboGenics NV, H1 2017
  19. Retinal Vein Occlusion - Dormant Projects, H1 2017
  20. Retinal Vein Occlusion - Discontinued Products, H1 2017

Access Retinal Vein Occlusion Pipeline Review H1 2017 Complete Report at www.reportsnreports.com/.aspx?name=1057919 .

 

News From

ReportsnReports - Industry Trends & ForecastsReportsnReports
Category: Market Research Publishers and RetailersCompany profile: ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision-making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets.